Skip to main content

Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials



This study investigated whether combination therapy with vasopressin, steroid, and epinephrine (VSE) improves in-hospital survival and return of spontaneous circulation (ROSC) during and after resuscitation in-hospital cardiac arrest (CA).

Materials and methods

Various databases were explored from inception until October 2021 for relevant published clinical trials and cohort studies.


Three clinical trials were included. Pooled analysis suggested that VSE was significantly associated with increased ROSC in patients with in-hospital CA (IHCA) (odds ratio (OR): 2.281, 95% confidence interval (CI): 1.304–3.989, P value = 0.004). Meta-analysis of two studies (368 patients) demonstrated a significant difference in the reduction of mean arterial pressure (MAP) during and 15–20 min after cardiopulmonary resuscitation (standardized mean difference (SMD): 1.069, 95% CI: 0.851–1.288, P value < 0.001), renal failure free days (SMD = 0.590; 95% CI: 0.312–0.869 days; P value < 0.001), and coagulation failure free days (SMD = 0.403; 95% CI: 0.128–0.679, P value = 0.004). However, no significant difference was observed for survival-to-discharge ratio (OR: 2.082, 95% CI: 0.638–6.796, P value = 0.225) and ventilator free days (SMD = 0.201, 95% CI: − 0.677, 1.079 days; P value = 0.838).


VSE combination therapy during and after IHCA may have beneficial effects in terms of the ROSC, renal and circulatory failure free days, and MAP.

Prospero registration: CRD42020178297 (05/07/2020).


Cardiac arrest (CA) is referred to as sudden loss of blood flow resulting from heart struggle to effectively pump blood to the brain and other vital organs [1]. Some physiological events, such as intense sympathetic stimulation and subsequent vasoconstriction, and the increased heart rate and respiratory drive occur that improve microcirculation, coronary perfusion, and cardiac contractility during CA [2]. Loss of consciousness, hypoxemia, and dyspnea are the main warning signs of this disorder. Some other signs and symptoms may also occur before CA, including chest pain, weakness, tachypnea, fluttering or palpitation; however, sudden CA often takes place with no warning signs. If CA is not treated within the initial minutes, it typically leads to death. The advanced cardiac life support (ACLS) guidelines recommend initiation of adult basic life support (BLS) algorithm and high-quality cardiopulmonary resuscitation (CPR). CPR and early defibrillation are fundamental steps for a successful life support in CA. In case of hypoxemia, supplemental oxygen is also recommended. Pharmacotherapy in CA includes administration of 1 mg of epinephrine every 3–5 min intravenously or intraosseously. If the second defibrillation fails, antiarrhythmic drugs of amiodarone or lidocaine should be initiated [3].

Epinephrine (EP) has been considered a main choice of life support for CA for decades [4]. Epinephrine is an active sympathomimetic hormone, stimulating alpha- (α) and beta (β)-adrenergic systems. EP increases the likelihood of achieving the return of spontaneous circulation (ROSC). However, high circulating catecholamines and overwhelming sympathetic tone are associated with oxidative stress and apoptosis of myocardiocytes. These neurohormonal events eventually lead to multiple organ dysfunction syndrome and are correlated with poor hemodynamic and neurological outcomes [5,6,7]. Some studies have shown that EP impairs the cerebral microcirculatory flow [8]. Once ROSC is achieved, excessive plasma concentrations of EP cause ventricular tachycardia, subsequent increase in oxygen demand, and ventricular fibrillation [9]. Therefore, attempts have been made to explore further drug combinations to reduce exogenous catecholamines requirements in cardiac arrest.

Vasopressin (VP), a non-adrenergic peripheral vasoconstrictor, causes narrowing of coronary and renal arteries. It has been considered as a therapeutic modality during CPR [10]. In-vitro studies have indicated that adjuvant therapy with exogenous VP during CPR is more effective than optimal doses of EP in improving blood flow to critical organs [11]. VP enhances the arterial and coronary perfusion pressure [12]. Unlike exogenous catecholamines, VP has minimal chronotropic effects and does not increase myocardial oxygen consumption [13]. At lower doses, VP activates the intravascular P2 purinergic and oxytocin receptors (OTR), through which, lower doses of VP mediate endothelial vasodilation, attenuate coronary vasoconstriction caused by V1 vascular receptors (V1Rs),and exert a positive inotropic effect [14, 15]. Moreover, VP stimulates secretion of cortisol directly through V1R and V3R on adrenal cortex [16]. However, the result of a previous systematic review of the randomized clinical trials (RCTs) could not display a benefit for VP, in combination with EP or only VP over EP, in improving survival of out-of-hospital cardiac arrest (OHCA) [17]. Thus, more investigations are needed to clarify the exact role of VP in management of CA [18].

Glucocorticoids (GCs) exert key metabolic influences on carbohydrate, lipid, and protein metabolism and maintenance of electrolyte and fluid balance. GCs increase blood glucose concentrations and accelerate glucose delivery during acute stress [19]. Endothelial glycocalyx is a combination of membrane-bound proteoglycans and glycoproteins covering endothelium luminally. Vascular endothelium is coated in endothelial glycocalyx, reduction of which increases capillary permeability [20]. Overwhelming systemic inflammatory responses contribute to glycocalyx shedding [21]. It has been demonstrated that endothelial glycocalyx plays a key role in pathophysiological events after CA, which is called as post-cardiac arrest syndrome (PCAS). Furthermore, serum levels of endothelial glycocalyx components are raised significantly immediately after CA [22]. Various studies have suggested that glycocalyx is a target for corticosteroids and this class of medications prevents endothelial glycocalyx shedding and diminishes interstitial swelling [23]. Previous studies have shown the adrenal insufficiency during CPR, manifested with a low serum cortisol concentration. Moreover, serum cortisol levels are lower in non-survivors of CA than survivors [24, 25]. Although, there are some evidence stating that GCs may have beneficial effects in CA, they suffer from low quality and fundamental flawed methodology.

Therefore, mechanically, it seems that the combination of these three drugs can be associated with better efficacy in IHCA via improving blood flow to critical organs and stabilization of endothelial glycocalyx barrier. As a result, several clinical trials have been designed to evaluate the effect of pharmacotherapy with the combination of these three drugs of vasopressin, epinephrine and glucocorticoids in CA patients, which have been associated with conflicting results in improving the return of spontaneous circulation during cardiopulmonary resuscitation and patient survival [26,27,28]. Considering the high mortality rate in CA victims, many attempts have been made to explore some therapeutic strategies to improve survival in CA. Although, the previous studies have assessed the effect of VP, EP, or GCs alone or in combination in CA, there is inconclusive evidence regarding combination therapy with VP, EP, and GCs (VSE) in the management of CA. Therefore, objective of the current study was to systematically review the existing literature on the efficacy of combination therapy with VSE in CA and investigating whether this combination therapy improves survival in victims of both in-hospital cardiac arrest (IHCA) and out of hospital cardiac arrest.


Protocol and registration

This systematic review was designed in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) statement and it was registered in the International Prospective Register of Systematic Reviews (PROSPERO) on May 2020 (Registration Number: CRD42020178297).

Data sources and search strategy

The keywords used in the present search strategy were selected from the medical subject headings (MeSH) database and other related non-MeSH terms. MEDLINE in PubMed (; National Library of Medicine), Scopus (, ISI Web of Science (, Cochrane central register for controlled trials ( and Google Scholar ( databases were searched for the following keywords: “Hydrocortisone” OR “Steroid” OR “Glucocorticoids” OR “Methylprednisolone” in combination with “Epinephrine” OR “Adrenaline” OR “EP” in combination with “Vasopressin” OR “Antidiuretic Hormones” in combination with “Cardiac Arrest” OR “Heart Arrest” OR “Sudden Cardiac Death” (Search strategy is presented in Additional file 1: Appendix A).

Eligibility criteria

Herein, the studies conducted on adult (aged ≥ 18 years) patients with CA (population), who had received VP (20 IU/CPR cycle) plus EP (1 mg/CPR cycle; cycle duration of approximately 3 min) or isotonic saline chloride placebo plus EP (1 mg/CPR cycle) for the first 5 CPR cycles after intervention were considered. Additional EP was administered afterwards if needed. Patients in the intervention group received methylprednisolone sodium succinate (40 mg) and those in the control group received isotonic saline chloride as placebo during the first CPR cycle. Patients with post-resuscitation shock were treated with stress dose of hydrocortisone (intervention and comparison). The selected studies had reported survival-to-discharge ratio, ROSC for 15 to 20 min or longer, and organ failure free days (outcomes).

Studies conducted on the subjects aged under 18 years, patients with terminal illness (life expectancy of 6 weeks), or undergone treatment with steroid within 1 month prior to hospital referral were excluded from the study.

Two investigators (FS and NB) scanned title and abstract carefully to exclude irrelevant papers and then, full text of the remained papers was evaluated. All the duplicated pooled records were removed automatically and manually via EndNote software (version X7).

Quality of evidence

A modified version of the Cochrane Collaboration’s tool [29,30,31] was used for assessing risk of bias in RCTs. Random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), and incomplete outcome data (attrition bias) were considered to summarize the quality of the selected studies. Each potential source of bias was graded as low, high, or unclear risk. A summary of overall assessment was provided by considering all the mentioned domains.

Outcomes and prioritization

Primary outcomes were ROSC within 15–20 min or longer. Secondary outcomes included survival-to-discharge ratio, number of organ failure free days, risk of complication and adverse events, neurological status and average mean arterial pressure (MAP) during and 15–20 min after CPR.

Data extraction

Three reviewers (FS, AS and NB) extracted the data using a standardized form of Cochrane Data Collection for Randomized Controlled Trials, independently. The following information was collected from each of the included studies: The family name of the first author, year of publication, country where the study was implemented, design of the study, baseline demographic and clinical characteristics of the patients, inclusion and exclusion criteria, primary and secondary outcomes, the drugs used in the intervention and control groups, and the intervention period.

Risk of bias assessment s in individual studies

Risk of bias in each of the included studies was independently assessed by 2 reviewers (NB and FS) using the Cochrane Collaboration risk of bias tool [32]. Six main domains of bias including selection, attrition, detection, performance, reporting bias and the other sources were evaluated using Review Manager software, which were finally classified as ‘low-risk’, ‘high-risk’, or unclear-risk studies. Studies that had a low risk of bias for all domains were regarded to have good quality; studies where one criterion was high risk or two criteria were unclear had fair quality, and the studies were listed as poor-quality studies if they had two or more items with high risk or unclear risk of bias.

Compliance with ethics guidelines

This systematic review and meta-analysis was carried out on published studies, so it does not involve any human or animal studies performed by the authors of this study. Shahid Sadoughi University of Medical Sciences, Yazd, Iran approved this research.

Statistical analysis

Standardized mean difference (SMD, Cohen’s d) and its corresponding standard error (SE) were calculated for continuous variables to be used as effect size for meta-analyses. For dichotomous variables, odds ratio (ORs) and their corresponding 95% confidence interval were derived and the logarithm of ORs and their corresponding SE were calculated as effect size [33]. Meta-analyses were performed using a random-effects model. Sensitivity analysis was conducted to determine the extent to which summary of the effects might depend on a particular study or a group of publications. In the case of significant asymmetry in funnel plots, trim -and-fill analysis was done to see if the overall effect was changed after establishing symmetry in the funnel plot. All the statistical analyses were done using Comprehensive Meta-Analysis Software (CMA) version 2. P values < 0.05 were considered as statistically significant.


Description of search

The primary searches on the previously mentioned databases resulted in identification of 53 papers with some overlaps between PubMed, Web of Science, SCOPUS, and EMBASE databases. No new paper was found by manual searching or searching on databases, such as Google Scholar. After removal of the duplicated papers, only 34 papers remained. Fourteen papers were excluded after screening the titles and abstracts (Tiab). After assessment of full texts of the studies, 17 papers were also excluded from further evaluation, because of irrelevant population and the type of studies. A total of three RCTs were eligible for including in the current systematic review and meta-analysis, carried out on 869 subjects [26,27,28]. The PRISMA flow diagram for screening inclusion/exclusion criteria in identification of the related papers is illustrated in Fig. 1.

Fig. 1
figure 1

PRISMA flow diagram and study selection process

Characteristics of the included studies

All of the studies were parallel RCTs and were written in English language. Among three RCTs, two studies were conducted in Greece [27, 28] and the other one in Denmark [26].

All the studies were published during 2009—2021. Duration of the studies varied between 10 and 30 months. The characteristics of the included studies are presented in Table 1.

Table 1 Characteristics of included studies of glucocorticoids in cardiac arrest

Risk of bias in the reviewed studies

The trials included in the current review were assessed for their quality using Cochrane Collaboration’s tool (Fig. 2). According to the Cochrane Collaboration Risk of Bias assessment, all the trials were classified to have good quality (i.e., low risk of bias for all domains).

Fig. 2
figure 2

Summary of risk of bias assessment in the reviewed studies


Survival to hospital discharge

As illustrated in Fig. 3a, combination therapy with VSE could not significantly increase the survival ratio (OR: 2.082, 95% CI: 0.638–6.796, P value = 0.225), while the heterogeneity was reported to be high (Cochrane Q test: I2 = 78.52%, P value = 0.010). Sensitivity analysis showed that Andersen et al. study [26] had an impact on the rate of hospital mortality; however, they did not affect the significance of the results (OR: 2.082, 95% CI: 0.638–6.796, P value = 0.225).

Fig. 3
figure 3

Forest plot illustrating meta-analysis of clinical trials investigated the effect of VSE combination therapy on survival ratio (a), ROSC ≥ 15 or 20 min (b), and ventilator free days (c)


The triple VSE combination therapy significantly increased the likelihood of ROSC sustained for at least 15 min (OR: 2.281, 95% CI: 1.304–3.989, P value = 0.004) (Fig. 3b) and heterogeneity was not significant (Cochrane Q test: I2 = 63.328, P value = 0.065). The results of sensitivity analysis showed that the effect size for the influence of VSE therapy on ROSC was robust after removing studies one by one (OR: 2.281, 95% CI: 1.304–3.989, P value = 0.004).

MAP during and 15–20 min after CPR

Pool analysis of two studies (368 patients) [27, 28] revealed that VSE combination therapy had a significant effect on MAP during (SMD: 1.069, 95% CI: 0.851–1.288, P value < 0.001) and 15–20 min (SMD: 0.831, 95% CI: 0.553–1.110, P value < 0.001) after CPR, and no between-study heterogeneity was observed (Cochrane Q test: I2 = 0.00, P value = 0.777).

Organ failure free days

Ventilator free days

The need for mechanical ventilation may indicate respiratory failure. All three studies (869 participants) reported data on ventilator free days [26,27,28]. The overall meta-analysis showed that there was no significant effect of VSE therapy on ventilator free days, while there was a high between-study heterogeneity (SMD = 0.201, 95% CI: − 0.677 to 1.079 days; P value = 0.838; Cochrane Q test: I2 = 95.466%; P value-heterogeneity < 0.001) (Fig. 3c).

Renal failure free days

Two trials including 368 participants reported data on renal failure free days [27, 28]. Meta-analysis of these two studies reported that VSE intervention had a significant effect on the renal failure free days parameter and no between-study heterogeneity was observed (SMD = 0.590; 95% CI: 0.312–0.869 days; P Value < 0.001; Cochrane Q test: I2 = 0.000%; P value-heterogeneity = 0.836).

Coagulation failure free days

Another organ failure free days, which was evaluated in two trials (368 participants) [27, 28] was coagulation failure free days. The results of meta-analysis indicated that VSE therapy was associated with a statistically significant reduction in coagulation failure free days, and the analysis had extremely low heterogeneity (SMD = 0.403; 95% CI: 0.128–0.679, P value = 0.004; Cochrane Q test: I2 = 0.000%; P value heterogeneity = 0.603).


Predefined potential adverse events, including hyperglycemia, pneumonia, electrolyte disturbance, gastrointestinal bleeding, and mesenteric and peripheral ischemia were also evaluated in eligible studies. The risk of adverse events was similar in both groups in all trials.


All three included studies, involving 869 patients assessed insulin requirement. Meta-analysis showed that VSE therapy is associated with a statistically significant higher numbers of patient days with insulin treatment aimed to reduce blood glucose level, and the analysis had extremely low heterogeneity (OR = 1.711; 95% CI: 1.324–2.212, P value < 0.001; Cochrane Q test: I2 = 0.000%; P value heterogeneity = 0.589).

Publication was not checked, because the asymmetry tests are not valid when the number of studies included in the meta-analysis are few. The summary of Meta-analysis on the effect of VSE triple therapy on different outcomes is illustrated in Table 2 using a random-effect model, based on the type of the study.

Table 2 Meta-analysis on the effect of VSE triple therapy on different reported outcomes using a random-effect model


The present systematic review and meta-analysis were performed to investigate the effect of combination therapy with VSE compared to EP plus isotonic saline chloride in patients with cardiac arrest. As presented by the results of the meta-analysis, triple therapy with epinephrine, vasopressin, and steroids significantly increased the likelihood of ROSC sustained for at least 15 min. Although the survival- to- discharge ratio did not achieve a statistical significance between intervention and control groups, but still favored VSE combination group.

ROSC is a sign of a sustained heart rhythm which perfused all body organs after CA. Symptoms of ROSC include a marked respiratory effort, cough, measurable blood pressure, or palpable pulse. Sustained ROSC is regarded when cardiopulmonary resuscitation is halted for at least 15–20 min and the circulation remains stable. Although ROSC is considered a primary outcome in all CA studies, it should be noted that the establishment of ROSC does not necessarily mean the higher survival and favorable outcome of CA victims [34]. Notably, the pathological events in CA are similar to shock syndromes. Similar to shock, failure to take prompt and timely treatment can lead to multiple organ failure (MOF) [35]. Therefore, one of the main outcomes assessed in CA studies is evaluation of MOF, as organ failure free days. Regarding long-term survivors, pool meta-analysis of 368 patients in these RCTs showed a significant increase in renal failure free days, and coagulation failure free days [27, 28]. Regarding the circulatory failure free days and ventilator free days, although the results were not significant, the trend of changes was in favor of the triple VSE combination therapy.

In survivors of CA, severe cerebral disability or vegetative status has the prevalence of 25–50%. Although all three studies evaluated neurological outcome, we could not perform meta-analysis for this variable because of different criteria and scoring scales used in these RCTs. In the study by Andersen et al., neurological status was measured by cerebral performance category (CPC) scale. Favorable neurological outcome was seen in 7.6% of patients in both intervention or control groups on day 30 with no significant difference between the two arms of the trial (P value > 0.99) [26]. In the study by Mentzelopoulos et al., the neurologically favorable survival to hospital discharge was assessed. The neurological failure was defined as Glasgow Coma Scale (GCS) < 9. The results of this trial showed a significant improvement in survival to hospital discharge with favorable neurological status [27]. In another study by Mentzelopoulos et al., only neurologic failure was measured as GSC < 9 as part of all-organ failure-free days with favorable results for VSE triple therapy [28].

To the best of our knowledge, no systematic review and extensive meta-analysis has been performed on the effect of VSE triple therapy in CA. Prior reviews have only assessed the effect of one or two drugs (monotherapy or dual therapy) in CA [3, 36,37,38,39,40,41]. In some recent systematic reviews and meta-analysis, the effect of steroids in CA was evaluated and indicated that steroid use after CA enhances ROSC and survival-to-discharge ratio in the patients with CA [41, 42]. In another meta-analysis, the therapeutic effects of VP were compared with combination therapy using EP and VP. However, this combination was not associated with the improved overall rates of ROSC, long-term survival, or favorable neurological outcomes [37].

The current study is one of few systematic reviews, in which all the included studies were high-quality RCTs and the dose of medications prescribed in the intervention and placebo groups was the same. Herein, three related RCTs were included in the systematic review and a total of 869 subjects were enrolled making the extracted results highly reliable. Given that, EP arm was the same in all the included subjects, the positive results observed in this meta-analysis, the increased ROSC rate appear to be related to administration of VP along with GCs.

Previously, three high-quality population-based cohort studies have shown that steroid supplementation during CPR improves hemodynamic stability, and is associated with high rates of ROSC, survival-to-discharge ratio, and 1-TH survival [43,44,45]. Mechanism of action of GCs is believed to be via inhibiting free-radical lipid peroxidation, oxidative stress, myocardial apoptosis, cerebral injury, and diminishing overwhelming systemic inflammatory responses,which take place following CA [22, 46, 47]. Furthermore, steroids provide protection against breaking down of endothelial glycocalyx barrier and interstitial swelling [23]. They also help in maintaining cardiovascular stability by preserving myocardial performance, inhibiting catecholamine reuptake, and enhancing vasoconstrictive properties of catecholamines to continue systemic vascular resistance [48]. Moreover, they strengthen contractile responsiveness by adrenergic augmentation [49]. On the other hand, available data have indicated that a low serum cortisol level is associated with unstable hemodynamics after ROSC and less survival rate [50].

The therapeutic effects of VP have been also extensively evaluated in CA. Rationale for using VP is derived from the studies demonstrated a relative deficiency of VP in patients with CA [51]. It is assumed that vasoplegia and pathologic vasodilation following ROSC contribute to a relative VP deficiency [52]. It has been shown that administration of vasopressors leads to an increase in plasma cortisol concentration and better perfusion to adrenal cortex and medulla, which helps in preservation of vascular tone [53].

Following CA, ischemia and damage to all tissues and organs take place, the main of which are brain injury, myocardial dysfunction, ischemia–reperfusion injury, and constant precipitating pathology [54]. These four components can determine the neurohormonal events following CA, even in patients who have rapidly achieved ROSC. Compensatory responses of the patient in face of these pathophysiological processes are aimed to maintain microcirculation, and improve coronary perfusion and contractile function of the heart [2]. Vasoplegia is a pathologic event presented with severe persistent hypotension (MAP < 50 mmHg), and low systemic vascular resistance despite normal or raised cardiac output [55]. It is frequently reported after ischemia–reperfusion syndrome, which itself is a major component of CA [56]. As mentioned, pool analysis of 368 patients [27, 28] revealed that VSE therapy increases MAP significantly during and 15–20 min after CPR.

There have been reports on the depressed VP levels in patients developed vasoplegia following other conditions. Administration of VP has been found to improve coronary and arterial perfusion through mediating P2 purinergic receptors, without causing additional load on the heart [14, 15]. VP induces the secretion of endogenous cortisol and improves vascular response to exogenous catecholamines [57, 58]. Moreover, VP enhances brain and renal vascular perfusion and calcium drive and attenuates the secretion of inflammatory cytokines. It seems that VP could lower mortality rate by improving blood flow to critical organs, decreasing the need for exogenous catecholamines and their subsequent adverse effects [59]. However, despite the presumed efficacy of this agent, the results of two systematic reviews and meta-analyses found no difference between the effects of using VP or norepinephrine on mortality rate in patients with CA [18, 37]. While in septic shock, the results of a meta-analysis indicated that mortality rate was significantly lower in the patients treated with VP or terlipressin compared to norepinephrine [60].

The concern with this combination treatment regimen is the risk of complication and adverse events. The results of the present meta-analysis showed that VSE was associated with a significant increase in insulin requirement. One well- known adverse effects of glucocorticoids is hyperglycemia, and a safe way for its management in hospitalized patients is administration of insulin. It is noteworthy that VSE patients, despite receiving more insulin, did not experience more frequent episodes of hyperglycemia. Regarding other potential adverse effects and possible complications, no significant difference was observed between the two study groups, including pneumonia.

Limitations of the study

Clinical trials are among the studies with the highest quality and most reliability and all the studies enrolled in this meta-analysis were clinical trials. Although, the enrolled RCTs were judged to have high quality, the results should be interpreted with caution. One major limitation of the included RCTs of this meta-analysis was comparison of three interventions simultaneously, making it difficult to discern which of the agents in VSE combination therapy exerts the positive effects observed in this population of the patients. Furthermore, it is yet indefinite whether each of these interventions alone can have beneficial effects on the patients with CA or VSE combination therapy has synergistic properties. Moreover, it is unclear whether the observed beneficial effects are due to the physiological effects of these drugs or a reduction in the need to exogenous vasopressors and their subsequent side effects; a case reported in Mentzelopoulos’ trial on 2009 which indicated that the use of this combination in 60-day follow-up significantly reduced the requirement for vasopressor [28]. If post-arrest myocardial function and physiological parameters were measured at different post-resuscitation times in these studies, then the results would be more reliable and give us a better overview of the exact process happening at neurohormonal level in CA. The last limitation was that, in spite of wide systematic search, a few relevant studies were eligible for inclusion in this meta-analysis.

Conclusion and the future prospects

The present study was the first investigation systematically reviewed the clinical studies on VSE triple therapy in CA. It was tried to cover all the existing literature in this field. Fortunately, dispersion of studies in this area was not high, they had similar design and they included common outcomes. Herein, three relatively uniform RCTs with high quality and low risk of bias were included. To the best of our knowledge, no systematic review and extensive meta-analysis have been recently performed on the effect of VSE triple therapy in CA.

The results of the current systematic review and meta-analysis indicated that triple therapy with EP, VP, and steroids compared to EP plus isotonic saline chloride significantly increased the likelihood of ROSC sustained for at least 15 min. Although the survival- to- discharge ratio did not achieve a statistical significance between intervention and control groups, but still favored VSE combination group.

For the future studies, it is recommended to determine the exact role of each component of this intervention and also who would be likely to benefit most from VSE combination therapy. Furthermore, it is suggested to explore the optimal dosage and duration of treatment with VSE during resuscitation and after achievement of ROSC. Moreover, the long-term influence of VSE combination therapy on post-arrest myocardial function, physiological parameters, and neurological outcomes of these patients should be studied in the future investigations.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.



Vasopressin, steroid, and epinephrine


Cardiac arrest


Mean arterial pressure


Return of spontaneous circulation


Advanced cardiac life support


Basic life support


Cardiopulmonary resuscitation






Oxytocin receptors


V1 vascular receptors


Randomized clinical trial


Out-of-hospital cardiac arrest




Post-cardiac arrest syndrome


In-hospital cardiac arrest


Multiple organ failure


Cerebral performance category


Glasgow Coma Scale


Odds ratio


Confidence interval


Standardized mean difference


  1. Andersen LW, Holmberg MJ, Berg KM, Donnino MW, Granfeldt A. In-hospital cardiac arrest: a review. JAMA. 2019;321(12):1200–10.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. Anesthesiol J Am Soc Anesthesiolog. 1992;77(4):662–8.

    CAS  Google Scholar 

  3. Finn J, Jacobs I, Williams TA, Gates S, Perkins GD. Adrenaline and vasopressin for cardiac arrest. Cochrane Database Syst Rev. 2019(1).

  4. Callaway CW. Epinephrine for cardiac arrest. Curr Opin Cardiol. 2013;28(1):36–42.

    Article  PubMed  Google Scholar 

  5. Blanco J, Muriel-Bombín A, Sagredo V, Taboada F, Gandía F, Tamayo L, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care. 2008;12(6):1–14.

    Article  Google Scholar 

  6. Schmittinger CA, Torgersen C, Luckner G, Schröder DC, Lorenz I, Dünser MW. Adverse cardiac events during catecholamine vasopressor therapy: a prospective observational study. Intensive Care Med. 2012;38(6):950–8.

    Article  CAS  PubMed  Google Scholar 

  7. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J Am Coll Cardiol. 2009;54(19):1747–62.

    Article  CAS  PubMed  Google Scholar 

  8. Paradis NA, Martin GB, Rivers EP, Goetting MG, Appleton TJ, Feingold M, et al. Coronary perfusion pressure and the return of spontaneous circulation in human cardiopulmonary resuscitation. JAMA. 1990;263(8):1106–13.

    Article  CAS  PubMed  Google Scholar 

  9. Nolan JP, Perkins GD. Is there a role for adrenaline during cardiopulmonary resuscitation? Curr Opin Crit Care. 2013;19(3):169–74.

    Article  PubMed  Google Scholar 

  10. Krismer AC, Dünser MW, Lindner KH, Stadlbauer KH, Mayr VD, Lienhart HG, et al. Vasopressin during cardiopulmonary resuscitation and different shock states. Am J Cardiovasc Drugs. 2006;6(1):51–68.

    Article  CAS  PubMed  Google Scholar 

  11. Lindner KH, Prengel AW, Brinkmann A, Strohmenger H-U, Lindner IM, Lurie KG. Vasopressin administration in refractory cardiac arrest. Ann Intern Med. 1996;124(12):1061–4.

    Article  CAS  PubMed  Google Scholar 

  12. Wenzel V, Lindner KH, Baubin MA, Voelckel WG. Vasopressin decreases endogenous catecholamine plasma concentrations during cardiopulmonary resuscitation in pigs. Crit Care Med. 2000;28(4):1096–100.

    Article  CAS  PubMed  Google Scholar 

  13. VanValkinburgh D, Kerndt CC, Hashmi MF. Inotropes and vasopressors. StatPearls [Internet]. 2021.

  14. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2—clinical physiology. Crit Care. 2003;8(1):1–9.

    Google Scholar 

  15. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1—receptor physiology. Crit Care. 2003;7(6):1–8.

    Article  Google Scholar 

  16. Heida JE, Minović I, van Faassen M, Kema IP, Boertien WE, Bakker SJ, et al. Effect of vasopressin on the hypothalamic–pituitary–adrenal axis in ADPKD patients during V2 receptor antagonism. Am J Nephrol. 2020;51(11):861–70.

    Article  CAS  PubMed  Google Scholar 

  17. Holmberg MJ, Issa MS, Moskowitz A, Morley P, Welsford M, Neumar RW, et al. Vasopressors during adult cardiac arrest: a systematic review and meta-analysis. Resuscitation. 2019;139:106–21.

    Article  PubMed  Google Scholar 

  18. Wyer PC, Perera P, Jin Z, Zhou Q, Cook DJ, Walter SD, et al. Vasopressin or epinephrine for out-of-hospital cardiac arrest. Ann Emerg Med. 2006;48(1):86–97.

    Article  PubMed  Google Scholar 

  19. Kim JJ, Lim YS, Shin JH, Yang HJ, Kim JK, Hyun SY, et al. Relative adrenal insufficiency after cardiac arrest: impact on postresuscitation disease outcome. Am J Emerg Med. 2006;24(6):684–8.

    Article  PubMed  Google Scholar 

  20. Reitsma S, Slaaf DW, Vink H, Van Zandvoort MA, Oude Egbrink MG. The endothelial glycocalyx: composition, functions, and visualization. Pflügers Arch Eur J Physiol. 2007;454(3):345–59.

    Article  CAS  Google Scholar 

  21. Kolářová H, Ambrůzová B, Švihálková Šindlerová L, Klinke A, Kubala L. Modulation of endothelial glycocalyx structure under inflammatory conditions. Mediat Inflam. 2014;2014:1–17.

    Article  Google Scholar 

  22. Grundmann S, Fink K, Rabadzhieva L, Bourgeois N, Schwab T, Moser M, et al. Perturbation of the endothelial glycocalyx in post cardiac arrest syndrome. Resuscitation. 2012;83(6):715–20.

    Article  PubMed  Google Scholar 

  23. Chappell D, Jacob M, Hofmann-Kiefer K, Bruegger D, Rehm M, Conzen P, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. J Am Soc Anesthesiolog. 2007;107(5):776–84.

    Article  CAS  Google Scholar 

  24. Lindner KH, Strohmenger HU, Ensinger H, Hetzel WD, Ahnefeld FW, Georgieff M. Stress hormone response during and after cardiopulmonary resuscitation. J Am Soc Anesthesiolog. 1992;77(4):662–8.

    Article  CAS  Google Scholar 

  25. Tavakoli N, Bidari A, Vahdati SS. Serum cortisol levels as a predictor of neurologic survival insuccessfully resuscitated victims of cardiopulmonary arrest. J Cardiovasc Thorac Res. 2012;4(4):107.

    PubMed Central  PubMed  Google Scholar 

  26. Andersen LW, Isbye D, Kjærgaard J, Kristensen CM, Darling S, Zwisler ST, et al. Effect of vasopressin and methylprednisolone vs placebo on return of spontaneous circulation in patients with in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2021;326:1586.

    Article  CAS  PubMed  Google Scholar 

  27. Mentzelopoulos SD, Malachias S, Chamos C, Konstantopoulos D, Ntaidou T, Papastylianou A, et al. Vasopressin, steroids, and epinephrine and neurologically favorable survival after in-hospital cardiac arrest: a randomized clinical trial. JAMA. 2013;310(3):270–9.

    Article  PubMed  Google Scholar 

  28. Mentzelopoulos SD, Zakynthinos SG, Tzoufi M, Katsios N, Papastylianou A, Gkisioti S, et al. Vasopressin, epinephrine, and corticosteroids for in-hospital cardiac arrest. Arch Intern Med. 2009;169(1):15–24.

    Article  CAS  PubMed  Google Scholar 

  29. Higgins JPTG. Cochrane handbook for systematic reviews of interventions version 5.1. 0 [updated March 2011]. The cochrane collaboration. 2011;20011.

  30. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64(4):407–15.

    Article  PubMed  Google Scholar 

  31. Macaskill P, Gatsonis C, Deeks J, Harbord R, Takwoingi Y. Cochrane handbook for systematic reviews of diagnostic test accuracy. Version 09 0 London: The Cochrane Collaboration. 2010;83.

  32. Higgins J. Cochrane handbook for systematic reviews of interventions. Version 5.1. 0 [updated March 2011]. The Cochrane Collaboration. 2011.

  33. Egger M, Davey-Smith G, Altman D. Systematic reviews in health care: meta-analysis in context. USA: Wiley; 2008.

    Google Scholar 

  34. Jacobs I, Nadkarni V, Arrest ITFoC, Outcomes CR, PARTICIPANTS C, Bahr J, et al. Cardiac arrest and cardiopulmonary resuscitation outcome reports: update and simplification of the Utstein templates for resuscitation registries: a statement for healthcare professionals from a task force of the International Liaison Committee on Resuscitation (American Heart Association, European Resuscitation Council, Australian Resuscitation Council, New Zealand Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Councils of Southern Africa). Circulation. 2004;110(21):3385–97.

    Article  PubMed  Google Scholar 

  35. Mongardon N, Dumas F, Ricome S, Grimaldi D, Hissem T, Pène F, et al. Postcardiac arrest syndrome: from immediate resuscitation to long-term outcome. Ann Intensive Care. 2011;1(1):1–11.

    Article  Google Scholar 

  36. Morales-Cané I, Valverde-León MDR, Rodríguez-Borrego MA. Epinephrine in cardiac arrest: systematic review and meta-analysis. Rev Latino-Am Enfermagem. 2016;24.

  37. Aung K, Htay T. Vasopressin for cardiac arrest: a systematic review and meta-analysis. Arch Intern Med. 2005;165(1):17–24.

    Article  CAS  PubMed  Google Scholar 

  38. Zhang Q, Liu B, Zhao L, Qi Z, Shao H, An L, et al. Efficacy of vasopressin-epinephrine compared to epinephrine alone for out of hospital cardiac arrest patients: a systematic review and meta-analysis. Am J Emerg Med. 2017;35(10):1555–60.

    Article  PubMed  Google Scholar 

  39. Mentzelopoulos SD, Zakynthinos SG, Siempos I, Malachias S, Ulmer H, Wenzel V. Vasopressin for cardiac arrest: meta-analysis of randomized controlled trials. Resuscitation. 2012;83(1):32–9.

    Article  CAS  PubMed  Google Scholar 

  40. Liu B, Zhang Q, Li C. Steroid use after cardiac arrest is associated with favourable outcomes: a systematic review and meta-analysis. J Int Med Res. 2020;48(5):0300060520921670.

    Article  PubMed Central  Google Scholar 

  41. Li Y, Zhang J, Cai N, He F. Efficacy and safety of corticosteroid therapy in patients with cardiac arrest: a systematic review of randomised controlled trials. Eur J Clin Pharmacol. 2020;1–8.

  42. Sahebnasagh A, Najmeddin F, Najafi A, Saghafi F, Salehi-Abargouei A, Ahmadi A, et al. Efficacy of glucocorticoid administration in patients with cardiac arrest: a systematic review of clinical studies. Curr Med Chem. 2021.

  43. Tsai M-S, Chuang PY, Yu PH, Huang C-H, Tang C-H, Chang W-T, et al. Glucocorticoid use during cardiopulmonary resuscitation may be beneficial for cardiac arrest. Int J Cardiol. 2016;222:629–35.

    Article  PubMed  Google Scholar 

  44. Tsai M-S, Chuang PY, Huang C-H, Tang C-H, Yu PH, Chang W-T, et al. Postarrest steroid use may improve outcomes of cardiac arrest survivors. Read Online Crit Care Med Soc Crit Care Med. 2019;47(2):167–75.

    CAS  Google Scholar 

  45. Niimura T, Zamami Y, Koyama T, Izawa-Ishizawa Y, Miyake M, Koga T, et al. Hydrocortisone administration was associated with improved survival in Japanese patients with cardiac arrest. Sci Rep. 2017;7(1):1–8.

    Article  CAS  Google Scholar 

  46. Aguilar D, Strom J, Chen QM. Glucocorticoid induced leucine zipper inhibits apoptosis of cardiomyocytes by doxorubicin. Toxicol Appl Pharmacol. 2014;276(1):55–62.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Katz L, Vaagenes P, Safa P, Diven W. Brain enzyme changes as markers of brain damage in rat cardiac arrest model. Effects of corticosteroid therapy. Resuscitation. 1989;17(1):39–53.

    Article  CAS  PubMed  Google Scholar 

  48. Grünfeld J-P, Eloy L. Glucocorticoids modulate vascular reactivity in the rat. Hypertension. 1987;10(6):608–18.

    Article  PubMed  Google Scholar 

  49. Ullian ME. The role of corticosteroids in the regulation of vascular tone. Cardiovasc Res. 1999;41(1):55–64.

    Article  CAS  PubMed  Google Scholar 

  50. Chalkias A, Xanthos T. Post-cardiac arrest syndrome: mechanisms and evaluation of adrenal insufficiency. World J Crit Care Med. 2012;1(1):4.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Jentzer JC, Chonde MD, Dezfulian C. Myocardial dysfunction and shock after cardiac arrest. BioMed Res Int. 2015;2015.

  52. Omar S, Zedan A, Nugent K. Cardiac vasoplegia syndrome: pathophysiology, risk factors and treatment. Am J Med Sci. 2015;349(1):80–8.

    Article  PubMed  Google Scholar 

  53. Kornberger E, Prengel AW, Krismer A, Schwarz B, Wenzel V, Lindner KH, et al. Vasopressin-mediated adrenocorticotropin release increases plasma cortisol concentrations during cardiopulmonary resuscitation. Crit Care Med. 2000;28(10):3517–21.

    Article  CAS  PubMed  Google Scholar 

  54. Neumar RW, Nolan JP, Adrie C, Aibiki M, Berg RA, Böttiger BW, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and Prognostication a consensus statement from the international liaison committee on resuscitation (American Heart Association, Australian and New Zealand Council on Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the Stroke Council. Circulation. 2008;118(23):2452–83.

    Article  PubMed  Google Scholar 

  55. Westerdahl DE, Kobashigawa JA. Heart transplantation for advanced heart failure. Cardiac Intensive Care. 2019;504.

  56. Jozwiak M, Bougouin W, Geri G, Grimaldi D, Cariou A. Post-resuscitation shock: recent advances in pathophysiology and treatment. Ann Intensive Care. 2020;10(1):1–11.

    Article  Google Scholar 

  57. Hajjar LA, Vincent JL, Barbosa Gomes Galas FR, Rhodes A, Landoni G, Osawa EA, et al. Vasopressin versus norepinephrine in patients with vasoplegic shock after cardiac surgery: the VANCS randomized controlled trial. Anesthesiology. 2017;126(1):85–93.

    Article  CAS  PubMed  Google Scholar 

  58. Perraudin V, Delarue C, Lefebvre H, Contesse V, Kuhn J, Vaudry H. Vasopressin stimulates cortisol secretion from human adrenocortical tissue through activation of V1 receptors. J Clin Endocrinol Metab. 1993;76(6):1522–8.

    CAS  PubMed  Google Scholar 

  59. McIntyre WF, Um KJ, Alhazzani W, Lengyel AP, Hajjar L, Gordon AC, et al. Association of vasopressin plus catecholamine vasopressors vs catecholamines alone with atrial fibrillation in patients with distributive shock: a systematic review and meta-analysis. JAMA. 2018;319(18):1889–900.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  60. Neto AS, Nassar AP, Cardoso SO, Manetta JA, Pereira VG, Espósito DC, et al. Vasopressin and terlipressin in adult vasodilatory shock: a systematic review and meta-analysis of nine randomized controlled trials. Crit Care. 2012;16(4):1–10.

    Google Scholar 

Download references


The authors would like to gratefully thank the Department of Clinical Pharmacy, School of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran, for their executive supports.


The study was funded by Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, (Grant No. 7673), Yazd, Iran.

Author information

Authors and Affiliations



The authors’ responsibilities were as follows: FS and AS and ASA developed the study concept and designed the research; NB and FS conducted the electronic searches and study selection; AS, FS and NB conducted data extraction and tabulated data; FS, ASA and AS conducted the data analysis and interpretation of results; NB, FS and AS wrote the draft of the manuscript; FS, ASA and AS performed the critical review and revised the manuscript. All authors read and approved the final version.

Corresponding author

Correspondence to Adeleh Sahebnasagh.

Ethics declarations

Ethics approval and consent to participate

This systematic review and meta-analysis was carried out on published studies, so it does not involve any human or animal studies performed by the authors of this study.

Consent for publication

“Not applicable”.

Competing interests

All authors declare to have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Search strategy of the literature.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saghafi, F., Bagheri, N., Salehi-Abargouei, A. et al. Efficacy of combination triple therapy with vasopressin, steroid, and epinephrine in cardiac arrest: a systematic review and meta-analysis of randomized-controlled trials. j intensive care 10, 5 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: